Michael Engel, MD, PhD, attended the Vanderbilt University School of Medicine in Nashville, TN. He completed his Pediatric residency training and subspecialty training in Pediatric Hematology/Oncology at the Monroe Carell Jr. Children's Hospital at Vanderbilt.
Dr. Engel's clinical interests encompass hematologic and oncologic illness in children, adolescents and young adults, with an emphasis on hematologic malignancies including myeloid and lymphoid leukemias.
Dr. Engel is a past recipient of a National Young Investigator award from the American Society of Pediatric Hematology/Oncology, a Ruth Kirschstein fellowship from the National Cancer Institute, a young investigator award from Alex's Lemonade Stand Pediatric Cancer Research Foundation, and served as a Hyundai Hope on Wheels Foundation Scholar. His research is currently supported by a Research Scholar Award from the St. Baldrick's Pediatric Cancer Research Foundation, research grants from CureSearch and Hope Street Kids foundations and a K08 Career Development Award from the National Institutes of Health. In the clinical setting, Dr. Engel is the recipient of a prestigious PRC Top Performer Award for 100th percentile patient satisfaction.
Education History
| Research Fellow |
Vanderbilt University Medical Center Department of Biochemistry |
Research Fellow |
|---|---|---|
| Fellowship |
Vanderbilt University Medical Center Pediatric Hematology/Oncology |
Clinical Fellow |
| Residency |
Vanderbilt University Medical Center Pediatrics – Special Alternative Pathway Trainee |
Resident |
| Professional Medical |
Vanderbilt University School of Medicine Medical Scientist Training Program |
M.D. |
| Doctoral Training |
Vanderbilt University School of Medicine Medical Scientist Training Program |
Ph.D. |
| Other Training |
Vanderbilt University School of Medicine Medical Scientist Training Program |
|
| Undergraduate |
Purdue University, West Lafayette Campus Biology |
B.S. |
Selected Publications
- Singer J, Andrade D, Bareyan D, McClellan D, Lucente H, Velinder M, Chandrasekharan M, Theisen E, Liu F, Sharma S, Maese L and Engel ME (2013). Notch alters sumoylation to govern GFI1 protein stability and support its transcriptional repression function [Abstract]. American Society of Hematology National Meeting, New Orleans, LA.
- Singer J, Andrade D, Bareyan D, McClellan D, Lucente H, Velinder M, Chandrasekharan M, Theisen E, Liu F, Sharma S and Engel ME (2013). Lysine Specific Demethylase-1 inhibition as a therapeutic strategy that leverages the requirement for Growth Factor Indepndence-1 in Notch-driven T-ALL [Abstract]. American Association for Cancer Research-Pediatric Oncology Working Group--Pediatric Cancer at the Crossroads-Translating discovery into improved outcomes.
- Mixon BA, Eckrich MJ, Lowas S, Engel ME (2013). Vincristine, irinotecan, and temozolomide for treatment of relapsed alveolar rhabdomyosarcoma. J Pediatr Hematol Oncol, 35(4), e163-6.
- Andrade D, Maese L, Singer J, Bareyan D, McClellan D, Lucente H, Quinton R, Chandrasekharan M, Liu F, and Engel ME (2013). Sumoylation regulates the half-life of Growth Factor Independence (GFI)-1 to modulate transcriptional repression [Abstract]. ASPHO National Meeting, Miami, FL.
- Andrade D, Singe J, Bareyan D, McClellan D, Lucente H, Chandrasekharan M, and Engel ME (2013). Notch and PIAS3 differentially regulate sumoylation of GFI1 to modulate transcriptional repression [Abstract]. AACR National Meeting, Washington, DC.
- Fagan E, Slone J, Shoemaker A, Black J, Berlin J, Engel ME (April 2012). Neuroendocrine carcinoma in an adolescent with hypercortisolemia. J Pediatr Hematol Oncol, 34(3), 117-119.
- Andrade DL, Bareyan D, Singer J, Quinton R, Engel ME (2012). Regulation of GFI1 proteins by Notch intracellular domains [Abstract]. American Association for Cancer Research National Meeting.
- Barrett CW, Smith JJ, Lu LC, Markham N, Stengel KR, Short SP, Zhang B, Hunt AA, Fingleton BM, Carnahan RH, Engel ME, Chen X, Beauchamp RD, Wilson KT, Hiebert SW, Reynolds AB, Williams CS (2012). Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters. PLoS One, 7(12), e51205.
- Mangrum DS, Shams S, Downie J, von Schwelder U, Rodic V, Engel ME, Barnette P, Frazer JK, Trede N, Pei D, Cheng C, Mullighan C, Yang J, Miles R, Schiffman JD (2011). Focal 22q11.22 loss combined with IKZF1 alterations predict very poor outcome in childhood acute lymphoblastic leukemia [Abstract]. American Society of Hematology National Meeting, San Diego, CA.
- Engel ME, and Hiebert SW (2010). Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia. In Lalitha Nagarajan, PhD (Eds.), Cancer Treatment and Research (Acute Myelogenous Leukemia-Genetics, Biology and Therapy, 145, pp. 127-147). New York: Springer.
- Engel ME, Hiebert SW (2010). The enemy within: dormant retroviruses awaken. Nat Med (16(5), pp. 517-8). United States.
- Engel ME, Nguyen HN, Mariotti J, Hunt A, Hiebert SW (2010). Myeloid translocation gene 16 (MTG16) interacts with Notch transcription complex components to integrate Notch signaling in hematopoietic cell fate specification. Mol Cell Biol, 30(7), 1852-63.
- Mariotti J, Nguyen HN and Engel ME (2010). Structure—function relationships between RUNX1-MTG fusion proteins and core components of the Notch transcription complex [Abstract]. American Association for Cancer Research National Meeting. Washington, DC.
- Chyla BJ, Moreno-Miralles I, Steapleton MA, Thompson MA, Bhaskara S, Engel M, Hiebert SW (2008). Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation. Mol Cell Biol, 28(20), 6234-47.
- Frangoul H, Wills M, Crossno C, Engel M, Domm J (2007). Acyclovir-resistant herpes simplex virus pneumonia post-unrelated stem cell transplantation: a word of caution. Pediatr Transplant, 11(8), 942-4.
- Engel ME, Hickstein DD, Bauer TR Jr, Calder C, Manes B, Frangoul H (2006). Matched unrelated bone marrow transplantation with reduced-intensity conditioning for leukocyte adhesion deficiency. Bone Marrow Transplant, 37(7), 717-8.
- Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL (2001). Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell, 12(1), 27-36.
- Engel ME, McDonnell MA, Law BK, Moses HL (1999). Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem, 274(52), 37413-20.
- Engel ME (1999). Rho GTP-Binding Proteins and the C-Jun N-Terminal Kinase Cascade. Ph.D. Thesis. Vanderbilt University.
- Sarkar DK, Pastorcic M, De A, Engel M, Moses H, Ghasemzadeh MB (1998). Role of transforming growth factor (TGF)-beta Type I and TGF-beta type II receptors in the TGF-beta1-regulated gene expression in pituitary prolactin-secreting lactotropes. Endocrinology, 139(8), 3620-8.
- Engel ME, Datta PK, Moses HL (1998). RhoB is stabilized by transforming growth factor beta and antagonizes transcriptional activation. J Biol Chem, 273(16), 9921-6.
- Engel ME, Datta PK, Moses HL (1998). Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. [Review]. J Cell Biochem Suppl, 30-31, 111-22.
- Kawabata M, Imamura T, Miyazono K, Engel ME, Moses HL (1995). Interaction of the transforming growth factor-beta type I receptor with farnesyl-protein transferase-alpha. J Biol Chem, 270(50), 29628-31.
- Engel ME, Vedvick T, Urcan M, Buckholz R, and Kinney J (1993). Expression System for Bovine Pancreatic Trypsin Inhibitor (BPTI/Aprotinin) Peptides. U.S. Patent No. US5258302. Washington, D.C.:U.S. Patent and Trademark Office.
- Vedvick T, Buckholz RG, Engel M, Urcan M, Kinney J, Provow S, Siegel RS, Thill GP (1991). High-level secretion of biologically active aprotinin from the yeast Pichia pastoris. J Ind Microbiol, 7(3), 197-201.